ArticleJournal for immunotherapy of cancer2026
USP1-mediated lipophagy-lipogenesis axis drives cholangiocarcinoma progression and immune evasion.
Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in PD-L1 Targeted Molecular Imaging Radiotracers Research: From Preclinical Exploration to Clinical Application.Molecular imaging and biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCholangiocarcinoma (CCA), a malignancy arising from biliary epithelial cells, features a tumor microenvironment (TME) characterized by metabolic dysregulation and immunosuppression. Although diverse metabolic aberrations have been observed, the dominant metabolic driver remains unclear. Therefore, the study aims to elucidate the molecular connections between metabolic reprogramming and immune evasion, and to provide the basis for developing TME-targeted therapies.
methodsFirst, untargeted metabolomics was performed to identify key metabolite classes involved in CCA progression. We subsequently used next-generation sequencing combined with database analysis to identify the key genes involved in tumor fatty acid metabolism. Metabolomics, proteomics and metabolic phenotyping experiments were subsequently performed to investigate this metabolic process. Tumor malignancy was evaluated using a range of in vitro and in vivo models. Single-cell RNA sequencing, Olink proteomics, flow cytometry and multiplex immunohistochemistry were performed to analyze the changes in the TME. Finally, we used humanized NOG mice to evaluate the efficacy of the combination therapy.
resultsIntegrated multi-omics analysis revealed that long-chain unsaturated fatty acids (LCUFAs) were enriched in CCA tissues and closely associated with tumor progression. Ubiquitin-specific peptidase 1 (USP1) was upregulated in CCA tissues, driving dynamic lipid metabolic reprogramming and was associated with poor prognosis. Mechanistically, USP1 orchestrated LCUFAs accumulation through coordinating the enhancement of lipophagy and lipogenesis, establishing a systems-level metabolic regulatory network. Tumor-secreted LCUFAs were preferentially internalized by tumor-associated macrophages (TAMs) through FABP5, thereby suppressing cytotoxic T cells activity. Additionally, TAMs upregulated USP1 in CCA cells, forming a positive feedback loop that perpetuates the metabolic-immune crosstalk.
conclusionIn summary, based on multi-omics analysis, this study establishes a systemic mechanism that links tumor lipid metabolism, immune suppression, and therapeutic response in CCA. Targeting the USP1-mediated metabolic-immune axis not only significantly suppresses tumor progression but also enhances the efficacy of immunotherapy. These findings construct a conceptual framework that integrates metabolic reprogramming, immune evasion, and treatment sensitivity, thereby establishing USP1 as a precision therapeutic target with broad biological and clinical importance for patients with CCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.